DE60007668D1 - Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes - Google Patents

Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes

Info

Publication number
DE60007668D1
DE60007668D1 DE60007668T DE60007668T DE60007668D1 DE 60007668 D1 DE60007668 D1 DE 60007668D1 DE 60007668 T DE60007668 T DE 60007668T DE 60007668 T DE60007668 T DE 60007668T DE 60007668 D1 DE60007668 D1 DE 60007668D1
Authority
DE
Germany
Prior art keywords
vaccine
submucosal
live attenuated
produce
attenuated bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60007668T
Other languages
English (en)
Other versions
DE60007668T2 (de
Inventor
Antonius Arnoldus Chris Jacobs
Danny Goovaerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE60007668D1 publication Critical patent/DE60007668D1/de
Publication of DE60007668T2 publication Critical patent/DE60007668T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/82—Viral vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60007668T 1999-01-26 2000-01-20 Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes Expired - Lifetime DE60007668T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200202 1999-01-26
EP99200202 1999-01-26

Publications (2)

Publication Number Publication Date
DE60007668D1 true DE60007668D1 (de) 2004-02-19
DE60007668T2 DE60007668T2 (de) 2004-12-02

Family

ID=8239828

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60007668T Expired - Lifetime DE60007668T2 (de) 1999-01-26 2000-01-20 Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes

Country Status (10)

Country Link
US (2) US20040120970A1 (de)
EP (1) EP1023903B1 (de)
JP (1) JP4339978B2 (de)
AT (1) ATE257713T1 (de)
AU (1) AU761515B2 (de)
CA (1) CA2296965A1 (de)
DE (1) DE60007668T2 (de)
DK (1) DK1023903T3 (de)
ES (1) ES2214217T3 (de)
PT (1) PT1023903E (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
WO2009004995A1 (ja) * 2007-06-29 2009-01-08 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. 生理活性物質を定着および発現させる方法
GB0801326D0 (en) * 2008-01-24 2008-03-05 Animal Health Trust Vaccines
KR101210082B1 (ko) * 2010-10-15 2012-12-07 주식회사 동방 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법
KR101694676B1 (ko) * 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
US20210290702A1 (en) 2018-08-10 2021-09-23 Meiji Seika Pharma Co., Ltd. Bacteriophage preparation
CN112973157A (zh) * 2021-02-04 2021-06-18 广西田东锦盛化工有限公司 一种用于氯碱生产的盐水浓缩装置
CN113244664A (zh) * 2021-05-12 2021-08-13 伍俊雄 一种用于疫苗破乳及分离的装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033223B (en) * 1978-09-01 1983-09-14 Secr Social Service Brit Antigen fromstreptococcus mutans for protection against dental caries
JPS6037734B2 (ja) 1978-10-12 1985-08-28 住友電気工業株式会社 管状臓器補綴材及びその製造方法
DE3263103D1 (en) 1981-06-19 1985-05-23 Secr Social Service Brit Protection against dental caries
IE940698L (en) 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
BE1008103A3 (fr) 1994-04-22 1996-01-16 Pantochim Sa Procede de preparation de catalyseurs au vanadium et phosphore et leur utilisation pour la production d'anhydride maleique.
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US5895756A (en) 1997-04-11 1999-04-20 The Board Of Trustees Of The University Of Texas System Non-antibiotic system for selection of recombinant mycobacteria
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
US6344201B1 (en) 1998-03-31 2002-02-05 Anthony T. Maurelli Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections

Also Published As

Publication number Publication date
US20110123571A1 (en) 2011-05-26
DE60007668T2 (de) 2004-12-02
DK1023903T3 (da) 2004-05-10
ATE257713T1 (de) 2004-01-15
JP4339978B2 (ja) 2009-10-07
CA2296965A1 (en) 2000-07-26
AU761515B2 (en) 2003-06-05
US8084040B2 (en) 2011-12-27
EP1023903A1 (de) 2000-08-02
AU1355700A (en) 2000-07-27
PT1023903E (pt) 2004-04-30
US20040120970A1 (en) 2004-06-24
ES2214217T3 (es) 2004-09-16
JP2000309542A (ja) 2000-11-07
EP1023903B1 (de) 2004-01-14

Similar Documents

Publication Publication Date Title
DE69526854T2 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
UY26256A1 (es) Amidas de ácidos carboxílicos, medicamentos que contienen estos compuestos, su utilización y su preparación
CY1105721T1 (el) Δερματικοι αναισθητικοι παραγοντες
DE60026844D1 (de) Verfahren zur herstellung von 3,3-dimethylbutanal
DE60007668D1 (de) Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes
ATE401309T1 (de) Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
DE60117651D1 (de) Bioabbaubare Zusammensetzung und Verfahren zur deren Herstellung
DE60100858D1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
ATE404665T1 (de) Methode zur herstellung hypermutierender bakterien
DE3072187D1 (de) Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung.
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
DE69824794D1 (de) Streptococcus equi Impfstoff
ATE307214T1 (de) Verfahren zur herstellung einer aus pflanzen stammenden, antibakteriellen substanz
DE69901243D1 (de) Artikulator zur herstellung von zahnärztlichen prothesen
DE69924741D1 (de) Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur vorbeugung und behandlung von parodontitis
DE69812438T2 (de) Zusammensetzung zur herstellung von brennstoff-briketts
DE60032293D1 (de) Lebende attenuierte bakterien zur verwendung als impfstoff
ATE124449T1 (de) Mikrobiologisches verfahren zur herstellung von hydroxylierten heterocyclen.
DE60014103D1 (de) Verfahren zur herstellung von debromohymenialdisin und deren analogen
ATE125866T1 (de) Typ ii-restriktionsendonuklease swai.
ATE238261T1 (de) Verfahren zur herstellung von orthoestern
ATE266403T1 (de) Verwendung von 2-methyl-thiazolidin 2,4- dicarbonsäure zur herstellung eines medikaments zur behandlung von infektionskrankheiten
DE50113668D1 (de) Verfahren zur herstellung von mintlacton

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INTERVET INTERNATIONAL B. V., AN BOXMEER, NL